Priyanka Sharma, MD

Dr. Priyanka Sharma is a Professor of Medicine at the University of Kansas Medical Center and assistant director of clinical research and co-program leader for the Drug Discovery, Delivery & Experimental Therapeutics program at the University of Kansas Cancer Center. She is the institutional principal investigator for South West Oncology Group (SWOG) and co-PI for MCA-KUCC NCORP grant.

Dr. Sharma received her medical degree from MS University of Baroda, India and proceeded to complete Internal Medicine residency, chief residency, and Hematology-Oncology fellowship at the University of Kansas Medical Center. Her research interests include clinical and translational research in triple-negative breast cancer (TNBC) and novel treatment strategies for metastatic breast cancer.

Dr. Sharma is recipient of several grants including American Society of Clinical Oncology (ASCO) Advanced Clinical Research Award, Mary-Kay Foundation grant and is principle investigator of several ongoing clinical trials with targeted agents.

Dr. Sharma is Vice-Chair of the South West Oncology Group (SWOG) Breast Committee, member of SWOG Board of Governors and member of NCI breast cancer steering committee.

I am a Professor of Medicine in the Department of Internal Medicine, Division of Oncology, as well as the Assistant Director for Clinical Research within the University of Kansas Cancer Center (KUCC). I am the Vice-Chair of the SWOG Breast Committee and have been member of the SWOG Board of Governors since 2015. I am a member of the American Society of Clinical Oncology (ASCO) scientific program committee, for which I also serve as breast cancer track leader for 2018-2019. In addition to national and institutional leadership roles, I am very actively involved in clinical and translational breast cancer research. My long-term research goal is to delineate personalized treatment strategies for triple-negative breast cancer (TNBC) and BRCA mutation-associated breast cancer. I serve as Translational PI of an ongoing CTEP-funded SWOG trial for patients with TNBC (S1416) and as PI of an active translational SWOG study (S9313c) which also focuses on TNBC. Outside of SWOG I have served as PI of several neoadjuvant therapeutic investigator-initiated trials for TNBC.

Association analysis identifies 65 new breast cancer risk loci

BRCA1 and BRCA2 Pathogenic Sequence Variants in Women of African Origin or Ancestry

Clinical activity of pembrolizumab in a patient with metastatic triple-negative breast cancer without tumor programmed death-ligand 1 expression: a case report and correlative biomarker analysis

Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer.

Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer [abstract]

Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: combined analysis of two cohorts

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

Impact of germline BRCA mutation status on survival in women with metastatic triple negative breast cancer [abstract]

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)

Impact of molecular subtypes on long-term outcomes in triple-negative breast cancer (TNBC) patients treated with adjuvant AC chemotherapy on SWOG S9313 [abstract]

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer

Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer [editorial]

Major strides in HER2 blockade for metastatic breast cancer [editorial]

Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel

Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).

Reducing breast cancer-related lymphedema (BCRL) through prospective surveillance monitoring using bioimpedance spectroscopy (BIS) and patient directed self-interventions

Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside

Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.

Drug repurposing screen for taxane-resistant triple-negative breast cancer

Evaluation of BRCAness as Prognostic Marker in Triple Negative Breast Cancer Patients Treated with Adjuvant Anthracycline Based Chemotherapy

Evaluation of longitudinal ctDNA to elucidate markers of response and acquired drug resistance to PI3K inhibitor therapy

Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer

Phase II trial of Neoadjuvant Carboplatin, Docetaxel plus Pembrolizumab in Stage I-III Triple-Negative Breast Cancer (NeoPACT)

Phase I/II trial of Nab-Paclitaxel and BYL-719 in Women with HER2 Negative Locally Recurrent or Metastatic Breast Cancer

Rapid Protease Profiling with a Multiplex Electronic Method for Detection of Metastatic Triple Negative Breast Cancer

The University of Kansas Cancer Center - Midwest Cancer Alliance Rural NCORP (KUCC-MCA Rural NCORP)